REVIEW

Benefits of reversible contraception [version 1; peer review: 3 approved]

Helena Kopp Kallner ^{1,2}¹Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden²Department of Obstetrics and Gynecology, Danderyd Hospital, Stockholm, Sweden**V1** First published: 29 Jun 2018, 7(F1000 Faculty Rev):973
<https://doi.org/10.12688/f1000research.14370.1>Latest published: 29 Jun 2018, 7(F1000 Faculty Rev):973
<https://doi.org/10.12688/f1000research.14370.1>

Abstract

Long-acting reversible contraception—intrauterine devices and contraceptive implants—offers the highest protection against unintended pregnancies. In addition, the use of reversible hormonal contraception has added health benefits for women in both the short and the long term. This review will give an overview of the benefits of reversible contraception as well as an evidence-based recommendation on how it should be used to benefit women the most.

Keywords

Contraception, unintended pregnancy, abortion, LARC

Open Peer Review

Approval Status

	1	2	3
version 1 29 Jun 2018

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Joseph Speidel**, University of California, San Francisco, USA
2. **Luis Bahamondes**, School of Medicine, University of Campinas (UNICAMP), Campinas, Brazil
3. **Melanie A Gold**, Columbia University Medical Center, New York, USA
Columbia University Mailman School of Public Health, New York, USA
New York-Presbyterian Hospital, New York, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Helena Kopp Kallner (Helena.Kopp-Kallner@ki.se)

Author roles: Kopp Kallner H: Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: HKK has served on advisory boards or as an invited speaker in educational events organized by Bayer Healthcare, MSD/Merck, Actavis, Evolan, Exeltis, Gedeon Richter, and Teva.

Grant information: The author is supported by a research grant from Stockholm County Council DNR: K0138-2015.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Kopp Kallner H. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kopp Kallner H. **Benefits of reversible contraception [version 1; peer review: 3 approved]** F1000Research 2018, 7(F1000 Faculty Rev):973 <https://doi.org/10.12688/f1000research.14370.1>

First published: 29 Jun 2018, 7(F1000 Faculty Rev):973 <https://doi.org/10.12688/f1000research.14370.1>

Introduction

In 2012, approximately 213 million pregnancies occurred worldwide¹. An unintended pregnancy is defined as a pregnancy that is unwanted or mistimed. In 2012, approximately 40% of all pregnancies were unintended, with 38% ending in live birth, 50% in abortion, and 13% in miscarriage¹. New data published in 2018 show that unintended pregnancies declined unevenly in the world, reflecting large differences in unmet need for contraception. In 2010–2014, 56% of unintended pregnancies ended in abortion, indicating that fewer women chose birth when confronted with an unintended pregnancy². Unintended and intended pregnancies alike may also result in the same proportion of miscarriage or ectopic pregnancy, which may result in subsequent subfertility or infertility.

It has been shown that long-acting reversible contraception (LARC)—intrauterine devices (IUDs) and contraceptive implants—offers the highest protection against unintended pregnancies. However, LARCs are rarely recommended for young women with high fertility. Short-acting reversible contraception (SARC) such as contraceptive pills, patches, rings, and injections are user dependent. Thus, the risk of getting pregnant because of inconsistent use is higher than for LARC.

In addition to protection against unintended pregnancy, the use of reversible hormonal contraception has added health benefits for women in both the short and the long term. The short-term added health benefits include a reduction of menstrual blood flow and protection against anemia, a reduction in dysmenorrhea and possible protection from symptoms of endometriosis, and a positive effect on mood in the premenstrual period. In the long term, all reversible contraception can be protective against some forms of cancer³.

In recent years, new ways of using reversible contraception have extended benefits for women and improved acceptability. This review will give an overview of the benefits of reversible contraception as well as an evidence-based recommendation on how it should be used to benefit women the most.

Protection against unintended pregnancy

In many parts of the world, unintended pregnancies arise from a lack of access to safe contraceptive methods. However, in parts of the world where efficient contraception is easily accessible, underutilization or user error is a common reason for contraceptive failure resulting in unintended pregnancy. Thus, reasons for unmet need of contraception vary in different settings. Most evidence on contraceptive use comes from women living in union (defined as traditional or legal marriage). Contraceptive use among young women not living in union in low-resource settings is less well known. Use of modern contraception was practiced globally by 57% of women living in union in 2015⁴. Therefore, presumably a large proportion of women globally have an unmet need for modern contraceptive methods.

LARC, such as subdermal implants and IUDs, results in significantly lower rates of unintended pregnancies owing to

less user error compared to other methods, especially among young users who have lower user adherence^{5,6}. LARCs also have higher satisfaction compared to SARC and higher continuation rates at 12 months⁷. After an induced abortion, the use of LARC has been shown to reduce subsequent induced abortions due to unintended pregnancy^{8–10}.

Although most women spend the majority of their fertile period trying to avoid pregnancy, the worldwide use of IUDs is estimated to be 14%⁴, and the use of implants is much lower⁴. In low-resource settings, the use of LARC is limited by access to health care professionals (HCPs) for placement and removal⁴.

Among barriers to using IUDs in high-resource settings, fear of pain at insertion is commonly stated^{11,12}. However, studies performed with an inserter 4.8 mm in diameter could not confirm that nulliparous women experience severe pain during insertion^{13,14}. Recent studies have included insertion tube diameters of 3.8 and 4.8 mm. These studies confirm that less than 7% of women experience severe pain with the 4.8 mm insertion tube but that significantly fewer experience such pain with a 3.8 mm insertion tube¹⁴. Thus, refraining from insertion of IUD in nulliparous women due to the patient's fear of experiencing severe pain is not in line with current evidence, although there is still an ongoing debate.

Ectopic pregnancy and the use of contraception

The focus on outcomes of unintended pregnancy tends to be on those that women can choose actively, i.e. abortion or birth. However, approximately 2% of all pregnancies are ectopic pregnancies^{15,16}, which is the leading cause of maternal mortality in the first trimester and accounts for approximately 9% of maternal mortalities in the US^{16–18}. LARC, such as IUDs, are user independent with a low risk of unintended pregnancy at 0.1–0.2% of women per user year^{6,19,20}. However, if pregnancy occurs, approximately 25–50% of these pregnancies are ectopic¹⁸. Thus, LARC use reduces the risk of ectopic pregnancy compared to SARC use.

Risk factors for ectopic pregnancy include previous history of ectopic pregnancy, pelvic surgery, pelvic infections (pelvic inflammatory disease [PID]) such as sexually transmitted infections including chlamydia trachomatis, assisted reproductive technology, smoking, and use of intrauterine contraception^{17,21}. These are generally not considered as contraindications for use of intrauterine contraception owing to the high contraceptive efficacy of the current devices and the failure rate of SARC due to inconsistent use.

Methods for reducing risks of unintended pregnancy due to inconsistent use of pills, patches, and rings

The most common combination contraceptive pills and the available patch and ring all come with a hormone-free period of 7 days, during which women typically have a withdrawal bleed. Follicle growth starts on day 1 in the normal menstrual cycle. That follicle growth and ovarian suppression would therefore be affected by the length of the

hormone-free period would seem logical, i.e. the longer time span without suppression, the larger the follicle grows and the closer the woman comes to ovulation. The benefit of a shorter hormone-free period has been previously suggested²². Research shows that escape ovulation may occur with a 7-day hormone-free period²³. Although these escape ovulations may be due to inconsistent use of the method, they may also be due to a short menstrual cycle where ovulation may occur as early as 10 days into the menstrual cycle. In this study, the formulation with a 4-day hormone-free period produced a higher level of ovarian suppression. The higher level of ovarian suppression with a 4-day hormone-free period compared to a 7-day hormone-free period was confirmed in another trial where the size of the ovarian follicle was measured²⁴. Thus, recommending a maximum 4-day hormone-free period may be beneficial when counseling women who wish to avoid pregnancy. The effectiveness of pills in typical use has been shown to be higher with a hormone-free period of 4 days compared with 7 days²⁵.

Short-term added health benefits with reversible contraception

Reduction in menstrual bleeding

Although choice of method may influence bleeding patterns and menstrual pain, recent research also focuses on how different methods can be used for the best effects on health and well-being. Using contraceptive pills/rings or patches for an extended but defined period of time may be called extended or long-cycle use. Using the same methods for longer periods of time until bleeding occurs may be called flexible continuous use. Recently, a Cochrane review evaluated continuous or extended use versus routine cyclic use of combined hormonal contraceptives for contraception²⁶. The review was based on 12 randomized controlled trials and concluded that there was no difference in compliance between regular 28-day cycles or extended or continuous use nor was there any difference in discontinuation or discontinuation due to experienced bleeding problems. The extended or continuous regimens fared better in terms of headaches, genital irritation, tiredness, bloating, and dysmenorrhea.

A recent study compared three groups of women. One group adhered to a 24/4 cycle, a second group took a 4-day pill-free break when experiencing a 3-day bleeding episode, and a third group could choose when to have a 4-day pill-free break. It was concluded that women in the second group had the fewest bleeding days during 1 year²⁷. There is evidence that the combined hormonal ring may also be used in continuous or extended regimens similar to those of pills²⁸. It is therefore possible that advising women on how to use their combined hormonal contraception may contribute more to user satisfaction than which combined hormonal pill is prescribed. There are no prospective studies comparing continuous or extended cycle use with a 24/4 regimen in terms of contraceptive effectiveness.

Evidence suggests that a newer formulation of combined hormonal contraceptive pills with estradiol valerate reduces

menstrual blood flow in women with heavy menstrual bleeding by as much as 90% when taken according to the manufacturer's instruction²⁹ compared to a reduction of 43% with older formulations taken with a 7-day hormone-free period³⁰. Taking pills with estradiol and norgestrel acetate reduces the number of cycles without any bleeding when compared to pills containing ethinyl estradiol and drospirenone if the pills are taken with a 24/4 or 21/7 regimen according to the manufacturer's instructions³¹. No comparative trials of bleeding patterns with extended or continuous regimens for pills containing estradiol/estradiol valerate or ethinyl estradiol have been published.

The most-effective method for reducing menstrual bleeding is the 52 mg levonorgestrel (LNG)-releasing intrauterine system (LNG-IUS)³². In addition to providing women with a reduction in menstrual bleeding, the LNG-IUS provides women with a highly effective LARC. Until a few years ago, the only available LNG was the 52 mg LNG-IUS approved for 4 or 5 years of use depending on the brand. New evidence suggests that one of the 52 mg LNG-IUS may be used beyond 5 years³³. There are now two additional LNG-IUS with hormone capsules containing 13.5 mg and 19.5 mg LNG, respectively. The 13.5 mg LNG-IUS is approved for 3 years of use, whereas the 19.5 mg LNG-IUS is approved for 5 years of use. All LNG-IUS reduce menstrual bleeding. The 52 mg LNG-IUS is approved for the treatment of heavy menstrual bleeding and has been shown to reduce bleeding by up to 92%^{32,34}. No such trials have been performed for the 13.5 mg or 19.5 mg LNG-IUS. In a randomized controlled trial comparing the three LNG-IUS, there were 23.6%, 18.9%, and 12.7% cycles without any bleeding in the 52 mg, 19.5 mg, and 13.5 mg LNG-IUS, respectively, at the end of the trial, which lasted for 3 years¹⁴. This makes a dose-response relationship in bleeding pattern likely. No comparative trials have been published for the treatment of heavy menstrual bleeding with extended- or continuous-use regimens of combined hormonal contraception and the LNG-IUS.

Premenstrual mood

It has been estimated that as many as 75% of women experience a negative effect on mood in the premenstrual phase and that approximately 3–5% of women have premenstrual dysphoric disorder with severe negative mood changes and experience social impairment because of this³⁵. The effect of hormonal contraception on premenstrual dysphoric syndrome/disorder has been investigated in reviews³⁶ and systematic reviews³⁷. These studies show that combined oral contraception improves premenstrual symptoms. A recent double blind randomized placebo-controlled trial of the effect on mood of a combined oral contraceptive containing 1.5 mg estradiol and norgestrel acetate showed a significant improvement of mood in the premenstrual phase in the intervention group³⁸. However, this was not a trial on premenstrual dysphoric syndrome/disorder but with normal, healthy women. Healthy women with mild premenstrual symptoms may thus be advised that combined hormonal contraception may have a beneficial effect on mood during the premenstrual phase. In

this trial, there was a non-significant worsening of mood in the early intermenstrual phase. However, the nocebo effect was pronounced, with as many as 17% of women in the placebo group and 24% of women in the intervention group indicating a worsening of mood during and after bleeding. Thus, a majority of women who indicate a worsening of mood may in fact experience a nocebo effect.

Long-term added health benefits

Effects on cancer

The effect of combined hormonal contraceptive pills on cancer has been studied in retrospective, prospective, and epidemiological studies. Results are partly consistent and partly contradictory. In 2017, the newest prospective data were published from the Royal College of General Practitioners' oral contraception study, which recruited women in Great Britain in 1968 and 1969³⁹. It concluded that ever use of combined oral contraceptives was associated with a reduced risk of colorectal cancer (incidence rate ratio 0.81; 99% confidence interval [CI] 0.66–0.99), endometrial cancer (incidence rate ratio 0.66; 99% CI 0.48–0.89), and ovarian cancer (incidence rate ratio 0.67; 99% CI 0.50–0.89). In addition, a reduction in lymphatic and hematopoietic cancer (incidence rate ratio 0.74; 99% CI 0.58–0.94) was seen. Several studies have shown an increase in breast cancer during current use of combined hormonal contraception, which was confirmed in a meta-analysis of these studies⁴⁰. However, this risk could not be confirmed in the Oxford Family Planning Association oral contraceptive study⁴¹. However, those studies that showed an increased risk also showed that this increased risk does not persist 5–15 years after stopping combined hormonal contraception, whereas the reduction in risks of ovarian, endometrial, and colon cancer persisted^{39,42,43}. In addition, no new increased cancer risks appeared later in life in any of the studies. In the large prospective Nurses' Health study with results published in 2014, it was concluded that groups with use or non-use of combined oral contraception did not differ in all-cause mortality⁴². In all large prospective studies, women were married and cohabitating. Women in the Nurses' Health study were 30–55 years old and nurses, whereas women in the Royal College of General Practitioners' oral contraception study had a median age of 29 at recruitment. Women in the Oxford Family Planning study were aged 25–39. In addition, the majority of women used oral contraceptives with 50 mcg of ethinyl estradiol, which is a higher dose than commonly used today. However, results are reassuring for women starting combined hormonal contraception today.

A recent large epidemiological study from Denmark studied the effect of modern contraceptives on breast cancer⁴³. The study showed similar results to previous studies in increased breast cancer risk for women with combined hormonal contraception. However, the study showed that current or recent LNG-IUS use was also associated with a small but significant increase in receiving a diagnosis of breast cancer with a relative risk of 1.21 (95% CI 1.11–1.33). The 52 mg LNG-IUS has been shown to be effective in the prevention of endometrial cancer⁴⁴. There are currently no studies which have studied the

long-term effect of LNG-IUS or low- or medium-dose progestin methods on ovarian or colon cancer risk, as these methods have not been on the market long enough.

Conclusion

Women in high- as well as low-resource settings experience the social, economic, and health consequences of unintended pregnancies. High sterilization rates limit women's reproductive choices and deny them access to the added benefits of reversible hormonal contraception. Apart from abortion and birth, which are options women may choose, unintended pregnancy may also result in ectopic pregnancy, which may threaten health and the future fertility of women. Women, and to some extent HCPs, are in many cases unaware and need increased information on the differences in effectiveness of different contraceptive methods and how methods should be used to improve effectiveness in typical use.

Fear of negative health effects of hormonal contraception remain an obstacle to the use of effective contraception for many women. Women fear a true but very small increased risk of breast cancer but remain ignorant of the many proven added health benefits of hormonal contraception, such as reduction in menstrual blood flow and menstrual pain and protection against certain cancers. There are also notions that the long-term health effects of hormonal contraception are somehow unknown and unexplored because of a lack of research. However, there are several large prospective, retrospective, and epidemiological studies of hormonal contraception which clearly show that these fears are exaggerated.

New large prospective studies on contraceptive use and especially the use of LNG-IUS and medium-dose progestin-only contraception and their effects on cancer and mood are lacking. Efforts should be made to carefully design these studies so that confounders can be controlled.

Reversible hormonal contraception has short-term as well as long-term benefits for women which deserve more attention from HCPs and women alike. If women are provided with more nuanced information regarding the risks and benefits of effective reversible contraception, they may make more informed decisions on the use of effective contraception and gain a higher quality of life.

Competing interests

HKK has served on advisory boards or as an invited speaker in educational events organized by Bayer Healthcare, MSD/Merck, Actavis, Evolan, Exeltis, Gedeon Richter, and Teva.

Grant information

The author is supported by a research grant from Stockholm County Council DNR: K0138-2015.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Sedgh G, Singh S, Hussain R: **Intended and unintended pregnancies worldwide in 2012 and recent trends.** *Stud Fam Plann.* 2014; **45**(3): 301–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Bearak J, Popinchalk A, Alkema L, *et al.*: **Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model.** *Lancet Glob Health.* 2018; **6**(4): e380–e389.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
3. Maguire K, Westhoff C: **The state of hormonal contraception today: established and emerging noncontraceptive health benefits.** *Am J Obstet Gynecol.* 2011; **205**(4 Suppl): S4–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. United Nations DoEaSA, Population Division: **Trends in Contraceptive Use Worldwide 2015.** 2015.
[Reference Source](#)
5. Trussell J: **Contraceptive failure in the United States.** *Contraception.* 2011; **83**(5): 397–404.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Winner B, Peipert JF, Zhao Q, *et al.*: **Effectiveness of long-acting reversible contraception.** *N Engl J Med.* 2012; **366**(21): 1998–2007.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
7. Peipert JF, Zhao Q, Allsworth JE, *et al.*: **Continuation and satisfaction of reversible contraception.** *Obstet Gynecol.* 2011; **117**(5): 1105–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Rose SB, Lawton BA: **Impact of long-acting reversible contraception on return for repeat abortion.** *Am J Obstet Gynecol.* 2012; **206**(1): 37.e1–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Cameron ST, Glasier A, Chen ZE, *et al.*: **Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy.** *BJOG.* 2012; **119**(9): 1074–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
10. Heikinheimo O, Gissler M, Suhonen S: **Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion.** *Contraception.* 2008; **78**(2): 149–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Asker C, Stokes-Lampard H, Beavan J, *et al.*: **What is it about intrauterine devices that women find unacceptable? Factors that make women non-users: a qualitative study.** *J Fam Plann Reprod Health Care.* 2006; **32**(2): 89–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Envall N, Groes Kofoed N, Kopp-Kallner H: **Use of effective contraception 6 months after emergency contraception with a copper intrauterine device or ulipristal acetate - a prospective observational cohort study.** *Acta Obstet Gynecol Scand.* 2016; **95**(8): 887–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Marions L, Lövkvist L, Taube A, *et al.*: **Use of the levonorgestrel releasing-intrauterine system in nulliparous women—a non-interventional study in Sweden.** *Eur J Contracept Reprod Health Care.* 2011; **16**(2): 126–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Gemzell-Danielsson K, Schellschmidt I, Apter D: **A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.** *Fertil Steril.* 2012; **97**(3): 616–22.e1–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
15. Farquhar CM: **Ectopic pregnancy.** *Lancet.* 2005; **366**(9485): 583–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Marion LL, Meeks GR: **Ectopic pregnancy: History, incidence, epidemiology, and risk factors.** *Clin Obstet Gynecol.* 2012; **55**(2): 376–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Li C, Zhao WH, Zhu Q, *et al.*: **Risk factors for ectopic pregnancy: a multi-center case-control study.** *BMC Pregnancy Childbirth.* 2015; **15**: 187.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
18. Barnhart KT: **Clinical practice. Ectopic pregnancy.** *N Engl J Med.* 2009; **361**(4): 379–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Rosenstock JR, Peipert JF, Madden T, *et al.*: **Continuation of reversible contraception in teenagers and young women.** *Obstet Gynecol.* 2012; **120**(6): 1298–305.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Heinemann K, Reed S, Moehner S, *et al.*: **Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.** *Contraception.* 2015; **91**(4): 280–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Moini A, Hosseini R, Jahangiri N, *et al.*: **Risk factors for ectopic pregnancy: A case-control study.** *J Res Med Sci.* 2014; **19**(9): 844–9.
[PubMed Abstract](#) | [Free Full Text](#)
22. Spona J, Elstein M, Feichtinger W, *et al.*: **Shorter pill-free interval in combined oral contraceptives decreases follicular development.** *Contraception.* 1996; **54**(2): 71–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Klipping C, Duijkers I, Trummer D, *et al.*: **Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.** *Contraception.* 2008; **78**(1): 16–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Christin-Maitre S, Serfaty D, Chabbert-Buffet N, *et al.*: **Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, norgestrel acetate and 17 β -estradiol (NOMAC/E2): a double-blind, randomized study.** *Hum Reprod.* 2011; **26**(6): 1338–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Dinger J, Minh TD, Buttmann N, *et al.*: **Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.** *Obstet Gynecol.* 2011; **117**(1): 33–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Edelman A, Micks E, Gallo MF, *et al.*: **Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.** *Cochrane Database Syst Rev.* 2014; (7): CD004695.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
27. Jensen JT, Garie SG, Trummer D, *et al.*: **Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.** *Contraception.* 2012; **86**(2): 110–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Sulak PJ, Smith V, Coffee A, *et al.*: **Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial.** *Obstet Gynecol.* 2008; **112**(3): 563–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
29. Jensen JT, Parke S, Mellinger U, *et al.*: **Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.** *Obstet Gynecol.* 2011; **117**(4): 777–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. Fraser IS, McCarron G: **Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia.** *Aust N Z J Obstet Gynaecol.* 1991; **31**: 66–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Mansour D, Verhoeven C, Sommer W, *et al.*: **Efficacy and tolerability of a monophasic combined oral contraceptive containing norgestrel acetate and 17 β -oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.** *Eur J Contracept Reprod Health Care.* 2011; **16**(6): 430–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
32. Lethaby A, Hussain M, Rishworth JR, *et al.*: **Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.** *Cochrane Database Syst Rev.* 2015; (4): CD002126.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
33. McNicholas C, Swor E, Wan L, *et al.*: **Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.** *Am J Obstet Gynecol.* 2017; **216**(6): 586.e1–586.e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. Heikinheimo O, Gemzell-Danielsson K: **Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS).** *Acta Obstet Gynecol Scand.* 2012; **91**(1): 3–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Bixo M, Johansson M, Timby E, *et al.*: **Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder.** *J Neuroendocrinol.* 2018; **30**(2).
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Freeman EW, Halbreich U, Grubb GS, *et al.*: **An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.** *Contraception.* 2012; **85**(5): 437–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Lopez LM, Kaptein AA, Helmerhorst FM: **Oral contraceptives containing drospirenone for premenstrual syndrome.** *Cochrane Database Syst Rev.* 2009; (2): CD006586.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Lundin C, Danielsson KG, Bixo M, *et al.*: **Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial.** *Psychoneuroendocrinology.* 2017; **76**: 135–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. Iversen L, Sivasubramaniam S, Lee AJ, *et al.*: **Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.** *Am J Obstet Gynecol.* 2017; **216**(6): 580.e1–580.e9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

40. Zhu H, Lei X, Feng J, *et al.*: **Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies.** *Eur J Contracept Reprod Health Care.* 2012; **17**(6): 402–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Vessey M, Yeates D: **Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study.** *Contraception.* 2013; **88**(6): 678–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Charlton BM, Rich-Edwards JW, Colditz GA, *et al.*: **Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study.** *BMJ.* 2014; **349**: g6356.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
43. Mørch LS, Skovlund CW, Hannaford PC, *et al.*: **Contemporary Hormonal Contraception and the Risk of Breast Cancer.** *N Engl J Med.* 2017; **377**(23): 2228–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
44. Beining RM, Dennis LK, Smith EM, *et al.*: **Meta-analysis of intrauterine device use and risk of endometrial cancer.** *Ann Epidemiol.* 2008; **18**(6): 492–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Melanie A Gold**

¹ Department of Paediatrics, Columbia University Medical Center, New York, USA

² Department Population and Family Health, Columbia University Mailman School of Public Health, New York, USA

³ School Based Health Centers, New York-Presbyterian Hospital, New York, USA

Competing Interests: No competing interests were disclosed.

2. **Luis Bahamondes**

Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, University of Campinas (UNICAMP), Campinas, SP, Brazil

Competing Interests: No competing interests were disclosed.

3. **Joseph Speidel**

Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research